[1] TORRE LA, ISLAMI F, SIEGEL RL, et al. Global cancer in women: burden and trends[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 444. doi: 10.1158/1055-9965.EPI-16-0858
[2] ANASTASIADI Z, LIANOS GD, IGNATIADOU E, et al. Breast cancer in young women: an overview[J]. Updates Surg, 2017, 69(3): 313. doi: 10.1007/s13304-017-0424-1
[3] SHI P, CHEN C, YAO Y. Correlation between HER-2 gene amplification or protein expression and clinical pathological features of breast cancer[J]. Cancer Biother Radiopharm, 2019, 34(1): 42. doi: 10.1089/cbr.2018.2576
[4] 郭晨明, 吴楠, 郭丽英. 我国HER-2阳性乳腺癌预后影响因素的Meta分析[J]. 中国普通外科杂志, 2016, 25(2): 264.
[5] DI OTO E, BRANDES AA, CUCCHI MC, et al. Prognostic impact of HER-2 Subclonal Amplification in breast cancer[J]. Virchows Arch, 2017;471(3): 313. doi: 10.1007/s00428-017-2151-x
[6] 张俊杰, 杨晓棠, 杜笑松, 等. 隐匿性乳腺癌的MRI表现及临床病理特征[J]. 中华肿瘤杂志, 2018, 40(1): 40.
[7] WAKS AG, WINER EP. Breast cancer treatment: A review[J]. JAMA, 2019, 321(3): 288. doi: 10.1001/jama.2018.19323
[8] LI X, ZHAO C, SU C, et al. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China[J]. BMC Cancer, 2016, 16(1): 828. doi: 10.1186/s12885-016-2875-z
[9] NITTA H, KELLY BD, ALLRED C, et al. The assessment of HER2 status in breast cancer: the past, the present, and the future[J]. Pathol Int, 2016, 66(6): 313. doi: 10.1111/pin.12407
[10] 江泽飞, 邵志敏, 徐兵河, 等. 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识2016[J]. 中华医学杂志, 2016, 96(14): 1091. doi: 10.3760/cma.j.issn.0376-2491.2016.14.006
[11] 陶维静, 胡春洪, 柏根基, 等. 乳腺癌MRI强化特征与免疫组织化学相关性分析[J]. 临床放射学杂志, 2016, 35(5): 706.
[12] MANNELLI L, NOUGARET S, VARGAS HA, et al. Advances in diffusion weighted imaging[J]. Radiologic clinics of North America, 2015, 53: 569. doi: 10.1016/j.rcl.2015.01.002
[13] 程雪, 余日胜, 徐民, 等. 乳腺癌的功能磁共振成像征象与人表皮生长因子受体2表达差异的相关性分析[J]. 中华医学杂志, 2019, 99(31): 2440. doi: 10.3760/cma.j.issn.0376-2491.2019.31.007
[14] 张丽, 韩立新, 曹惠霞, 等. 3.0T磁共振扩散加权成像和VIBRANT动态增强在鉴别乳腺腺病与乳腺癌中的价值[J]. 临床放射学杂志, 2017, 36(3): 342.
[15] 陈倩, 沈玉英, 蔡庆, 等. 乳腺癌MRI表现与CerbB-2、Ki-67表达的相关性研究[J]. 临床放射学杂志, 2016, 35(10): 1486.
[16] PARK SH, CHOI HY, HAHN SY. Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion weighted MRI at 3.0 Tesla[J]. JMRI, 2015, 41(1): 175. doi: 10.1002/jmri.24519
[17] 李敏红, 陈德基, 罗永良, 等. 乳腺癌的MRI影像学特征与细胞分子表型之间的相关性研究[J]. 临床放射学杂志, 2015, 34(1): 36.
[18] LI X, LI Y, ZHU Y, et al. Association between enhancement patterns and parameters of contrast-enhanced ultrasound and microvessel distribution in breast cancer[J]. Oncol Lett, 2018, 15(4): 5643.
[19] 孙双燕, 杨长良, 黄志成, 等. 不同分子亚型乳腺癌MRI特征分析[J]. 中国临床医学影像杂志, 2017, 28(5): 327. doi: 10.3969/j.issn.1008-1062.2017.05.007
[20] HA R, JIN B, MANGO V, et al. Breast cancer molecular subtype as a predictor of the utility of preoperative MRI[J]. AJR, 2015, 204(6): 1354. doi: 10.2214/AJR.14.13666
[21] 郭斌. 乳腺癌病人腋窝淋巴结转移相关因素分析[J]. 蚌埠医学院学报, 2021, 46(2): 206.